CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11864-023-01109-9.pdf
Reference62 articles.
1. McAndrew NP, Finn RS. Clinical review on the management of hormone receptor–positive metastatic breast cancer. JCO Oncology Practice. 2022;18(5):319–27.
2. •• Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–50. Final OS analysis of the randomized, double-blind, placebo-controlled, phase III MONALEESA-2 trial with ribociclib plus letrozole demonstrating OS benefit in the front line.
3. Neven PFP, Chia S, Jerusalem G, Im S, Petrakova K, Bianchi G, Martin Jimenez M, Nusch A, Sonke GS, de la Cruz merino L, Zarate JP, Wang Y, Chakravatty A, Wang C, Slamon D. editor Updated overall survival (OS) results from the first-line population in the phase III MONALEESA-3 trial of postmenopausal patients with HR+HER2- advanced breast cancer treated with ribociclib + fulvestrant. ESMO Breast Cancer Congres; 2022.
4. •• M.P. Goetz MT, J. Huober, J. Sohn, O. Tredan, I.H. Park, M. Campone, S.C. Chen, L.M. Manso Sanchez, S. Paluch-Shimon, G. van Hal, A. Shahir, H. Iwata, S. Johnston, editor MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). ESMO Congress; 2022. Second interim OS analysis from the randomized, double-blind, placebo-controlled, phase III MONARCH-3 trial with abemaciclib plus AI demonstrating OS benefit in front line.
5. •• Lu Y-S, Im S-A, Colleoni M, Franke F, Bardia A, Cardoso F, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2− advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2022;28(5):851–9. (Exploratory OS analysis with extended follow-up (median 53.5 months) for the randomized, double-blind, placebo-controlled, phase III MONALEESA-7 trial showing consistent OS benefit with ribociclib plus ET in peri/premenopausal patients in the front line.)
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3